Health Economics and Outcomes Research (hEOR) is a unit of the Galen Centre for Health and Social Policy and seeks to support and inform healthcare decisions, views and statements with relevant scientific evidence.


Health Economics and Outcomes Research (hEOR), seeks to make significant positive contributions in healthcare by using relevant scientific evidence to inform healthcare decision-making in all strategies, policies and operations for all agencies.

hEOR supports better health care policies by offering insights in economics; and statistical analyses of critical issues. With that hEOR endeavours to use evidence based scientific analysis to help decision makers make informed, and timely decisions.


hEOR’s strategic perspective stresses on projects tackling policy and strategic issues that have effects on the present and will shape the future.

hEOR believes in working diligently, and closely with stakeholders, clients and external experts to: develop significant new policy insights; define strategies, and identify optimal choices.


L22, Common Ground
G016, Jaya One
72A, Jln Professor Diraja Ungku Aziz, Seksyen 13
46200 Petaling Jaya, Selangor, Malaysia

T: +6012 336 2338
E: [email protected]


  • Use relevant scientific evidence to “inform” better health care decision making
  • Drive health economics and outcomes research to connect into a complicated synergy between health systems; and economic theory, its models and techniques; and healthcare decisions made based on evidence
  • Build an active knowledge sharing community and network for health economics and outcomes research


Provides consultancy services for non-profit and for-profit purposes:

  • Scientific research based on evidence. This is based on the core of health economics, economic evaluations, budget impact analysis, value assessments and generations of real-world evidence.
  • Health economics training sessions: Typically all training sessions can be designed for all organizations. Academic excellence in all courses are monitored by a global panel of professors. Training is broken into basic, intermediate and advanced modules.
  • Knowledge sharing opportunities in the form of Health Economic Forums.
  • Personalized case studies and clinical studies upon contract and agreement.

informing healthcare decisions

The hEOR Team


Dr. June W. Y. Choon

Principal Science Officer

With more than 10 years of experience in pharmacy, Dr. June Choon began her career as a front-line hospital pharmacist but discovered very early on that her forte lay in academic pharmacy and related scientific research. She has done more than twenty bioavailability and bioequivalence studies for local pharmaceuticals during her Ph.D training in Universiti of Sains Malaysia.

Dr. Choon is a published former academic with Monash University, and in her eight years in tenure, she was appointed as Chair of the Monash Health Economics Forum and drove its knowledge sharing endeavours with support from the Pharmaceutical Services Division, Ministry of Health, Pharmaceutical Association of Malaysia (PhAMA).

Simultaneously, Dr. Choon continued to train with the University of York. Where her focus research areas included: cardiovascular, psychiatry, oncology and real-world evidence. Also, throughout her career, she has sat in various research ethics committees and advisory for pharmaceuticals.

Researchers & Collaborators

Kenneth Lee

Prof. Kenneth Kwing-Chin Lee

Distinguished Fellow

Prof. Lee is widely recognised as one of the pioneers in pharmacoeconomics and outcomes research in Asia. He was the founding president of the Hong Kong Chapter of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He was Professor and Associate Director of External Affairs of the CUHK School of Pharmacy, of which he was a founding member before he moved to Malaysia.

Prof Lee has served in a number of leadership positions in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). In May 2012, he was elected a member of ISPOR Board of Directors for 2012-4. He was the major driving force and later a founding member of the first ISPOR regional consortium – ISPOR Asia Consortium which was established in 2004. He served as President of the Consortium from 2006-2008. Prof Lee is currently a committee member of the ISPOR Award Council responsible for all the major annual awards.

Dato Faridah

Dato’ Dr Faridah Aryani Md. Yusof

Distinguished Fellow

Dr. Faridah has extensive experience in drug regulatory affairs working in various positions in the National Pharmaceutical Regulatory Agency (NPRA) for over a period of 18 years, and designated as the Secretary to the Drug Control Authority. She was appointed as the Director of NPRA. She held a few top posts in the Pharmaceutical Services Programme (PSP) and, was promoted as the Senior Director for the PSP in 2020. Being the Senior Director for Pharmaceutical Services, she headed the pharmacy services for the entire country. She retired ending 34.5 years of service in the government, and now serving the Pharmacy School, USM as an Academic Fellow.

Dr. Faridah graduated as a pharmacist and obtained her PhD in Pharmacoeconomics in 2006 from Universiti Sains Malaysia.


Prof. Asrul A Shafie

Distinguished Fellow

Asrul A Shafie completed his PhD degree in 2008. His research interests are in pharmacoeconomic, and health service research where he has published more than 300 peer reviewed journal articles and books/monographs with H-Index of 39. He is the editorial board member for Pharmacoeconomics and Value in Health Asian Region journal. He is currently the Board Member for HTAsiaLink Network, and core member of ISPOR Code of Ethics Task Force.

He is also an appointed expert member for the UK National Institute for Health Research Committee, Malaysia Health Technology Assessment Agency (MaHTAS), Malaysia Pharmacoeconomic Guidelines Development Committee, Malaysia Institute of Health Service Research, Malaysia Pharmacy Advisory Board and Malaysia Pharmacoeconomic Technical Committee.

At present, Dr Asrul is the Professor of Pharmacoeconomic and Director for Institutional Planning & Strategic Centre in Universiti Sains Malaysia.

Lana Lai

Dr. Lana Lai


Lana Lai is a medical statistician at the University of Manchester, UK with an interest in digital learning health systems. She has a background in pharmacy and has experience working with real-world observational studies encompassing a wide range of research methodologies and data sources in the US and UK.

She is also part of Observational Health Data Sciences and Informatics (OHDSI), a global network of scientists working to bring out the value of observational health data through large-scale analytics. To date, she has published more than 30 papers, including characterising patients with COVID-19 and method evaluation in vaccine safety surveillance.